Precision BioSciences, Inc.
TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
Last updated:
Abstract:
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
Status:
Application
Type:
Utility
Filling date:
26 Jan 2022
Issue date:
12 May 2022